Trade

with

TrovaGene Inc
(NASDAQ: TROV)
AdChoices
4.45
+0.02
+0.45%
After Hours :
-
-
-

Open

4.66

Previous Close

4.43

Volume (Avg)

34.23k (163.16k)

Day's Range

4.41-4.66

52Wk Range

2.97-7.91

Market Cap.

84.12M

Dividend Rate ( Yield )

-

Beta

-0.73

Shares Outstanding

18.90M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 259.25k

    • Net Income

    • -11.81M

    • Market Cap.

    • 84.12M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -3,772.74

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -0.73

    • Forward P/E

    • -6.36

    • Price/Sales

    • 322.58

    • Price/Book Value

    • 4.85

    • Price/Cash flow

    • -8.33

      • EBITDA

      • -11.66M

      • Return on Capital %

      • -42.44

      • Return on Equity %

      • -130.87

      • Return on Assets %

      • -42.44

      • Book Value/Share

      • 0.92

      • Shares Outstanding

      • 18.90M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Buy
        • 1 Year Price Target

        • 8.50

        • Credit Rating

        • -

        • Analysts

        • 2

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 13.50

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -3,762.86

            • 39.38

            • Net Profit Margin

            • -3,772.74

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.85

              • 0.76

              • Current Ratio

              • 17.70

              • 2.92

              • Quick Ratio

              • 17.55

              • 2.35

              • Interest Coverage

              • -119.39

              • 38.02

              • Leverage Ratio

              • 2.09

              • 2.21

              • Book Value/Share

              • 0.92

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.06

                • 196.08

                • P/E Ratio 5-Year High

                • -19.71

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.86

                • 124.82

                • Price/Sales Ratio

                • 303.03

                • 9.12

                • Price/Book Value

                • 4.58

                • 8.26

                • Price/Cash Flow Ratio

                • -8.33

                • 47.39

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -130.87

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -42.44

                        (-)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -64.55

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.01

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -10.69M
                      Operating Margin
                      -4,123.71
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -8.33
                      Ownership

                      Institutional Ownership

                      20.92%

                      Top 10 Institutions

                      20.21%

                      Mutual Fund Ownership

                      5.14%

                      Float

                      85.36%

                      5% / Insider Ownership

                      2.65%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Carnegie Global Healthcare

                      •  

                        250,000

                      • 0.00

                      • 1.30

                      • Vanguard Total Stock Mkt Idx

                      •  

                        247,726

                      • 0.00

                      • 1.31

                      • Eurizon EasyFund Eq North America LTE

                      •  

                        169,018

                      • 13.80

                      • 0.89

                      • Vanguard Extended Market Index Fund

                      •  

                        119,785

                      • 4.81

                      • 0.63

                      • iShares Micro-Cap

                      •  

                        65,745

                      • 1.28

                      • 0.34

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        57,904

                      • 0.00

                      • 0.31

                      • Octalfa 360 Enjeux d'Avenir

                      •  

                        25,000

                      • 0.00

                      • 0.14

                      • EB DL Non-SL Market Completion Fund

                      •  

                        12,810

                      • 217.55

                      • 0.07

                      • Vanguard US Equity Index

                      •  

                        7,600

                      • 0.00

                      • 0.04

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        4,592

                      • 0.00

                      • 0.02

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Bridger Management LLC

                      •  

                        2,142,857

                      • 0.00%

                      • 11.34

                      • Vanguard Group, Inc.

                      •  

                        365,262

                      • +5.64%

                      • 1.93

                      • Morgan Stanley Smith Barney LLC

                      •  

                        352,319

                      • +39.99%

                      • 1.86

                      • CAMBRIDGE Invest RESEARCH ADVISORS, INC.

                      •  

                        335,108

                      • -3.65%

                      • 1.77

                      • Carnegie Asset Management Fondsmæglersel

                      •  

                        250,000

                      • 0.00%

                      • 1.30

                      • Eurizon Capital S.A.

                      •  

                        169,023

                      • +13.80%

                      • 0.89

                      • BlackRock Fund Advisors

                      •  

                        69,623

                      • +2.95%

                      • 0.37

                      • Geode Capital Management, LLC

                      •  

                        65,494

                      • 0.00%

                      • 0.35

                      • Denver Investments

                      •  

                        43,541

                      • +126.80%

                      • 0.23

                      • Northern Trust Investments, N.A.

                      •  

                        32,897

                      • -1.64%

                      • 0.17

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Value

                      TrovaGene, Inc., was incorporated in the State of Delaware on April 26, 2002 as Used Kar Parts, Inc. On July 2, 2004, the Company acquired Xenomics, a California corporation, which was developing and commercializing TrDNA technology....more As part of the acquisition, its corporate name was changed to Xenomics, Inc. (Xenomics) The Company re-domesticated its state of incorporation from Florida to Delaware and its name was changed to Trovagene, Inc. It is a development stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. Its novel tests predominantly use transrenal DNA, or Tr-DNA, and transrenal RNA, or Tr-RNA. The Company is leveraging its proprietary urine-based molecular diagnostic technology for ...morethe detection of cell-free DNA and RNA originating from diseased cell death that can be isolated from urine and detected to improve disease management. These genetic materials are also collectively referred to as cell-free nucleic acids, which result when cells in the body die and release their DNA or RNA into the bloodstream. Its fundamental urine-based molecular diagnostic platform is protected by a strong intellectual property portfolio. The Company’s developed significant intellectual property around cell-free nucleic acids in urine, the extraction of cell-free nucleic acids from urine, as well as novel assay designs, particularly its proprietary non-naturally occurring primers. As of February 28, 2014, our property portfolio consists of over 130 issued patents and over 47 pending patent applications. The Company faces direct competition in the area of transrenal cell-free DNA or RNA detection and analysis is precluded by our growing patent estate. Its competitors include medical diagnostic companies, most of which have financial, technical, and marketing resources significantly greater than our resources.lessless

                      Key People

                      Dr. Antonius Schuh,PhD

                      CEO/Director

                      Dr. Thomas H. Adams,PhD

                      Chairman of the Board/Director

                      Stephen Zaniboni

                      CFO/Chief Accounting Officer

                      Dr. Rodney S. Markin,M.D.,PhD

                      Director

                      Gary S. Jacob

                      Director

                      • TrovaGene Inc

                      • 11055 Flintkote Avenue

                      • San Diego, CA 92121

                      • USA.Map

                      • Phone: +1 858 952-7570

                      • Fax: -

                      • trovagene.com

                      Incorporated

                      2002

                      Employees

                      21

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: